Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback